Investing.com – Pharmaceutical firm Eli Lilly missed Q3 earnings, revenues estimates.
Third-quarter non-GAAP EPS fell 1% yoy to $0.88 vs estimate of $0.96.
Revenues in the quarter rose 5% yoy to $5.19 bn but missed estimate of $5.25 bn.
Firm reaffirmed full-year non-GAAP EPS estimate of $3.50-$3.60.
President/CEO John C. Lechleiter to retire effective year-end; replaced by David A. Ricks.